New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
Immune Checkpoint Inhibitor MyocarditisÌýand Left Ventricular Systolic Dysfunction.
ÌÇÐÄ´«Ã½
Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction. JACC. CardioOncology Chen, Y. C., Dolladille, C., Rao, A., Palaskas, N. L., Deswal, A., Lehmann, L., Cautela, J., Courand, P. Y., Hayek, S., Zhu, H., Cheng, R. K., Alexandre, J., Baldassarre, L. A., Roubille, F., Laufer-Perl, M., Asnani, A., Ederhy, S., Tamura, Y., Francis, S., Gaughan, E. M., Johnson, D. B., Flint, D. L., Rainer, P. P., Bailly, G., Ewer, S. M., Aras, M. A., Arangalage, D., Cariou, E., Florido, R., Peretto, G., Itzhaki Ben Zadok, O., Akhter, N., Narezkina, A., Levenson, J. E., Liu, Y., Crusz, S. M., Issa, N., Piriou, N., Leong, D., Sandhu, S., Turker, I., Moliner, P., Obeid, M., Heinzerling, L., Chang, W. T., Stewart, A., Venkatesh, V., Du, Z., Yadavalli, A., Kim, D., Chandra, A., Zhang, K. W., Power, J. R., Moslehi, J., Salem, J. E., Zaha, V. G. 2025; 7 (3): 234-248Abstract
Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, but ICI myocarditis (ICI-M) remains a potentially fatal complication. The clinical implications and predictors of left ventricular ejection fraction (LVEF) <50% in ICI-M are not well understood.The aim of this study was to identify factors associated with LVEF <50% vs =50% at the time of hospitalization for ICI-M. A secondary objective was to evaluate the relationship between LVEF and 30-day all-cause mortality.The International ICI-Myocarditis Registry, a retrospective, international, multicenter database, included 757 patients hospitalized with ICI-M. Patients were stratified by LVEF as reduced LVEF (<50%) or preserved LVEF (=50%) on admission. Cox proportional hazards models were used to assess the associations between LVEF and clinical events, and multivariable logistic regression was conducted to examine factors linked to LVEF.Of 757 patients, 707 had documented LVEFs on admission: 244 (35%) with LVEF <50% and 463 (65%) with LVEF =50%. Compared with patients with LVEF =50%, those with LVEF <50% were younger (<70 years), had a body mass index of <25 kg/m2, and were more likely to have received chest radiation (24.2% vs 13.5%; P < 0.001). Multivariable analysis identified predictors of LVEF <50%, including exposure to v-raf murine sarcoma viral oncogene homolog B1/mitogen-activated protein kinase inhibitors, pre-existing heart failure, dyspnea at presentation, and at least 40 days from ICI initiation to ICI-M onset. Conversely, myositis symptoms were associated with LVEF =50%. LVEF <50% was marginally associated with 30-day all-cause mortality (unadjusted log-rank P = 0.062; adjusted for age, cancer types, and ICI therapy, HR: 1.50; 95% CI: 1.02-2.20).Dyspnea, time from ICI initiation, a history of heart failure, and prior cardiotoxic therapy may be predictors of an initial LVEF <50% in patients with ICI-M.
View details for
View details for